1. Home
  2. OBK vs PHAR Comparison

OBK vs PHAR Comparison

Compare OBK & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Bancorp Inc.

OBK

Origin Bancorp Inc.

HOLD

Current Price

$43.97

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$16.36

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBK
PHAR
Founded
1912
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
OBK
PHAR
Price
$43.97
$16.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
2
Target Price
$44.29
$38.00
AVG Volume (30 Days)
234.5K
31.8K
Earning Date
04-29-2026
01-01-0001
Dividend Yield
1.36%
N/A
EPS Growth
N/A
N/A
EPS
1.46
N/A
Revenue
N/A
N/A
Revenue This Year
$25.48
$27.75
Revenue Next Year
$5.79
$9.39
P/E Ratio
$30.12
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$28.80
$7.50
52 Week High
$46.02
$21.34

Technical Indicators

Market Signals
Indicator
OBK
PHAR
Relative Strength Index (RSI) 56.03 44.85
Support Level $42.75 $16.30
Resistance Level $45.05 $17.44
Average True Range (ATR) 1.24 0.67
MACD -0.29 -0.09
Stochastic Oscillator 20.49 44.04

Price Performance

Historical Comparison
OBK
PHAR

About OBK Origin Bancorp Inc.

Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: